Paper38487526
The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer.
Dou T and 7 others. Front Immunol, 2024. Cited by 21 papers, by iCite.
Cite this record
ConductScience Library. The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer. Papers, record 38487526. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38487526
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Female | |
| Humans | |
| Tumor Microenvironment | |
| Endothelial Cells | |
| Adipocytes | |
| Fibroblasts |
Source PubMed
References197
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27162480 | Immunotherapy with methyl gallate, an inhibitor of Treg cell migration, enhances the anti-cancer effect of cisplatin therapy. | Korean J Physiol Pharmacol | 2016 | https://conductscience.org/library/papers/27162480 | PubMed |
| 2 | 34579743 | Chemotherapy-triggered changes in stromal compartment drive tumor invasiveness and progression of breast cancer. | J Exp Clin Cancer Res | 2021 | https://conductscience.org/library/papers/34579743 | PubMed |
| 3 | 19305395 | Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. | Nat Immunol | 2009 | https://conductscience.org/library/papers/19305395 | PubMed |
| 4 | 30042442 | Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling. | Cell Death Dis | 2018 | https://conductscience.org/library/papers/30042442 | PubMed |
| 5 | 28574616 | The Therapeutic Potential of Targeting Tumor Microenvironment in Breast Cancer: Rational Strategies and Recent Progress. | J Cell Biochem | 2018 | https://conductscience.org/library/papers/28574616 | PubMed |
| 6 | 22516258 | Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. | Cancer Cell | 2012 | https://conductscience.org/library/papers/22516258 | PubMed |
| 7 | 30294328 | Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells. | Front Immunol | 2018 | https://conductscience.org/library/papers/30294328 | PubMed |
| 8 | 30134951 | IL-6-mediated cross-talk between human preadipocytes and ductal carcinoma in situ in breast cancer progression. | J Exp Clin Cancer Res | 2018 | https://conductscience.org/library/papers/30134951 | PubMed |
| 9 | 29774124 | Long-term exposure to carcinoma-associated fibroblasts makes breast cancer cells addictive to integrin β1. | Oncotarget | 2018 | https://conductscience.org/library/papers/29774124 | PubMed |
| 10 | 24002734 | Sulforaphane inhibits mammary adipogenesis by targeting adipose mesenchymal stem cells. | Breast Cancer Res Treat | 2013 | https://conductscience.org/library/papers/24002734 | PubMed |
| 11 | 30034942 | Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells. | Am J Cancer Res | 2018 | https://conductscience.org/library/papers/30034942 | PubMed |
| 12 | 27875786 | Inflammation, dysregulated metabolism and aromatase in obesity and breast cancer. | Curr Opin Pharmacol | 2016 | https://conductscience.org/library/papers/27875786 | PubMed |
| 13 | 31014367 | The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells. | Breast Cancer Res | 2019 | https://conductscience.org/library/papers/31014367 | PubMed |
| 14 | 20521754 | Treatment of breast cancer. | Am Fam Physician | 2010 | https://conductscience.org/library/papers/20521754 | PubMed |
| 15 | 22224776 | Immune regulatory function of B cells. | Annu Rev Immunol | 2012 | https://conductscience.org/library/papers/22224776 | PubMed |
| 16 | 31096176 | The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer. | Ann Diagn Pathol | 2019 | https://conductscience.org/library/papers/31096176 | PubMed |
| 17 | 27671678 | Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. | Cancer Res | 2016 | https://conductscience.org/library/papers/27671678 | PubMed |
| 18 | 20702612 | A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. | Clin Cancer Res | 2010 | https://conductscience.org/library/papers/20702612 | PubMed |
| 19 | 32849585 | The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion. | Front Immunol | 2020 | https://conductscience.org/library/papers/32849585 | PubMed |
| 20 | 34439387 | Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34439387 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42920907 | Molecular and immune-mediated resistance to antibody-drug conjugates in breast cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/42920907 | PubMed |
| 42357290 | Polymeric Nano Drug Delivery Systems for Overcoming Tumor Microenvironment-Mediated Drug Resistance. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42357290 | PubMed |
| 42347041 | A Multiresolution Breast Cancer CIBERSORTx Resource Validated for Accuracy, Interpretive Limits, and Biological and Clinical Coherence in Tumor Microenvironment Deconvolution. | Methods Protoc | 2026 | https://conductscience.org/library/papers/42347041 | PubMed |
| 42332744 | Decoding triple negative breast cancer bone metastasis: from 3D bioprinted models to clinical translation. | J Nanobiotechnology | 2026 | https://conductscience.org/library/papers/42332744 | PubMed |
| 42078644 | C-MPL signaling in breast cancer: molecular mechanisms and therapeutic implications. | Ann Med Surg (Lond) | 2026 | https://conductscience.org/library/papers/42078644 | PubMed |
| 41699782 | Therapeutic Effect of Gemcitabine Combined With Angelica Polysaccharide on Triple Negative Breast Cancer in Mice. | Integr Cancer Ther | 2026 | https://conductscience.org/library/papers/41699782 | PubMed |
| 41681885 | Targeting the Tumor Microenvironment in Triple-Negative Breast Cancer: Emerging Roles of Monoclonal Antibodies and Immune Modulation. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41681885 | PubMed |
| 41286375 | Impact of single-cell cell cycle regulation of intercellular communication on the prognosis of hepatocellular carcinoma in the tumor microenvironment. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/41286375 | PubMed |
| 40982113 | KLF4 in cancer chemoresistance: molecular mechanisms and therapeutic implications. | Discov Oncol | 2025 | https://conductscience.org/library/papers/40982113 | PubMed |
| 40968428 | Therapeutic Potential of Underexplored Phytoconstituents Targeting Molecular Pathways in Breast Cancer Subtypes. | Mini Rev Med Chem | 2025 | https://conductscience.org/library/papers/40968428 | PubMed |
| 40964989 | 3D Bioprinting and Artificial Intelligence for Tumor Microenvironment Modeling: A Scoping Review of Models, Methods, and Integration Pathways. | Mol Pharm | 2025 | https://conductscience.org/library/papers/40964989 | PubMed |
| 40520231 | Reference-free deconvolution of complex samples based on cross-cell-type differential analysis: Systematic evaluations with various feature selection options. | Front Genet | 2025 | https://conductscience.org/library/papers/40520231 | PubMed |
| 40005948 | Canine, Feline, and Murine Mammary Tumors as a Model for Translational Research in Breast Cancer. | Vet Sci | 2025 | https://conductscience.org/library/papers/40005948 | PubMed |
| 39944834 | Investigating the role of cathepsins in breast cancer progression: a Mendelian randomization study. | Front Oncol | 2025 | https://conductscience.org/library/papers/39944834 | PubMed |
| 39835122 | Single-cell mitophagy patterns within the tumor microenvironment modulate intercellular communication, impacting the progression and prognosis of hepatocellular carcinoma. | Front Immunol | 2024 | https://conductscience.org/library/papers/39835122 | PubMed |
| 39806516 | Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. | J Hematol Oncol | 2025 | https://conductscience.org/library/papers/39806516 | PubMed |
| 39769466 | Advancements in the Application of scRNA-Seq in Breast Research: A Review. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39769466 | PubMed |
| 39364737 | Polyphyllin II inhibits breast cancer cell proliferation via the PI3K/Akt signaling pathway. | Mol Med Rep | 2024 | https://conductscience.org/library/papers/39364737 | PubMed |
| 39154313 | Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. | Clin Transl Oncol | 2025 | https://conductscience.org/library/papers/39154313 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/38487526
GET https://conductscience.org/api/papers/v1/38487526/references?page=2